Announcements Trials
Browse Landscape

Phase

Phase 2 3

Status

Recruiting 1Not yet recruiting 1Active not recruiting 1

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Lymphoid 3

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell 10Lymphoma, Mantle-Cell 6Lymphoma, B-Cell 6Lymphoma, Non-Hodgkin 5Waldenstrom Macroglobulinemia 3Leukemia, B-Cell 3Hematologic Diseases 3Recurrence 2Lymphoma, B-Cell, Marginal Zone 2Lymphoma 2Lymphoma, Follicular 1Leukemia, Lymphoid 1Leukemia 1Hematologic Neoplasms 1Chromosome 17 deletion 1

Interventions

Rituximab 9venetoclax 7ibrutinib 7Cyclophosphamide 7Mycophenolic Acid 5fludarabine phosphate 4Whole-Body Irradiation 4Sirolimus 4zanubrutinib 3pirtobrutinib 3Peripheral Blood Stem Cell Transplantation 3Dexamethasone 3Cyclosporine 3ixazomib 2fludarabine 2carfilzomib 2acalabrutinib 2Tacrolimus 2Melphalan 2Etoposide 2Cyclosporins 2Calcium Dobesilate 2CT-P10 2Busulfan 2Bendamustine Hydrochloride 2talquetamab 1pembrolizumab 1loncastuximab tesirine 1brexucabtagene autoleucel 1Vincristine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Waldenstrom Macroglobulinemia × pirtobrutinib × 90 days × Clear all
NCT07231952 2026-06-03

A Study of Pirtobrutinib, Venetoclax, and Rituximab in People With Waldenström's Macroglobulinemia (WM)/Lymphoplasmacytic Lymphoma (LPL)

Memorial Sloan Kettering Cancer Center

Phase 2 Recruiting
40 enrolled
Lymphoid

Waldenstrom Macroglobulinemia, Lymphoma, B-Cell, Marginal Zone

NCT05734495 2026-05-28

Pirtobrutinib and Venetoclax in Waldenström Macroglobulinemia

Dana-Farber Cancer Institute

Phase 2 Active not recruiting
46 enrolled
Lymphoid

Waldenstrom Macroglobulinemia, Lymphoma, B-Cell, Marginal Zone

NCT07548450 2026-04-23

MPOWER

University of Utah

Phase 2 Not yet recruiting
25 enrolled
Lymphoid

Waldenstrom Macroglobulinemia

Data powered by HemOnc (CC BY 4.0) Colophon âš¡